Coya Therapeutics, Inc. Financing Cash Flow
Coya Therapeutics, Inc. (COYA) reported Financing Cash Flow of $10.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Coya Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$166.07K.
- Coya Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $11.00M, a 57356.17% increase year-over-year.
- Coya Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $20.35M, a 109.95% increase year-over-year.
- Coya Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $19.14K.
- Coya Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $20.39M, a 27.21% increase from fiscal 2024.
- Coya Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $16.03M, a 58.29% decline from fiscal 2023.
- Coya Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $38.43M, a 310.62% increase from fiscal 2022.
- Coya Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $9.36M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$166.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $10.83M 10-Q · filed 2026-08-11 | $31.18M derived: sum of 3 quarters · filed 2026-08-11 | $31.20M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $11.00M 10-Q · filed 2026-05-12 | $31.34M derived: sum of 2 quarters · filed 2026-05-12 | $31.36M derived: sum of 3 quarters · filed 2026-05-12 | $31.36M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $20.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $20.37M derived: sum of 2 quarters · filed 2026-03-16 | $20.37M derived: sum of 3 quarters · filed 2026-08-11 | $20.39M 10-K · filed 2026-03-16 |
| 2025-09-30 | $19.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $19.14K derived: sum of 2 quarters · filed 2026-08-11 | $38.27K 10-Q · filed 2025-11-12 | $9.73M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $19.14K 10-Q · filed 2026-08-11 | $9.71M derived: sum of 3 quarters · filed 2026-08-11 | $9.65M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $19.14K 10-Q · filed 2026-05-12 | $9.71M derived: sum of 2 quarters · filed 2026-05-12 | $9.65M derived: sum of 3 quarters · filed 2026-05-12 | $14.80M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $9.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $9.64M derived: sum of 2 quarters · filed 2026-03-16 | $14.79M derived: sum of 3 quarters · filed 2026-03-16 | $16.03M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$56.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $5.09M derived: sum of 2 quarters · filed 2025-11-12 | $6.33M 10-Q · filed 2025-11-12 | $30.51M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $5.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $6.39M 10-Q · filed 2025-08-12 | $30.57M derived: sum of 3 quarters · filed 2025-08-12 | $30.57M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.24M 10-Q · filed 2025-05-13 | $25.42M derived: sum of 2 quarters · filed 2025-05-13 | $25.42M derived: sum of 3 quarters · filed 2025-05-13 | $25.42M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $24.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $24.17M derived: sum of 2 quarters · filed 2025-03-18 | $24.17M derived: sum of 3 quarters · filed 2025-03-18 | $38.43M 10-K · filed 2025-03-18 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $14.25M 10-Q · filed 2024-11-06 | $14.15M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $14.25M 10-Q · filed 2024-08-12 | $14.15M derived: sum of 3 quarters · filed 2024-08-12 | $14.14M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $14.25M 10-Q · filed 2024-05-09 | $14.15M derived: sum of 2 quarters · filed 2024-05-09 | $14.14M derived: sum of 3 quarters · filed 2024-05-09 | $23.67M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$104.07K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$113.88K derived: sum of 2 quarters · filed 2024-03-19 | $9.42M derived: sum of 3 quarters · filed 2024-03-19 | $9.36M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$9.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $9.53M derived: sum of 2 quarters · filed 2023-11-08 | $9.46M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $9.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $9.47M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$65.23K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | -$340.58K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |